GENinCode UK Ltd. (GENI) AI Stock Analysis

• Market Cap: £8.03M
• Dividend Yield: N/A
• Average Volume (3M): 1.99M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.27
• Revenue Growth: 12.12%
• EPS Growth: 54.24%
• Country: UK
• Employees: 42
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 286,882,050
• 10 Day Avg. Volume: 166,671
• 30 Day Avg. Volume: 1,986,185
• PEG Ratio: 0.02
• Price to Book (P/B): 5.90
• Price to Sales (P/S): 2.46
• P/FCF Ratio: -1.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: 3.50p ▲(25.00% Upside)

GENinCode UK Ltd. faces significant financial challenges, with persistent losses and negative cash flows weighing heavily on its overall score. However, recent strategic partnerships and regulatory approvals provide a positive outlook for market expansion and product adoption, partially offsetting financial concerns. Technical indicators suggest moderate bullish momentum, but valuation remains a concern due to negative earnings.

Positive Factors

Revenue Growth

The company has shown a steady increase in revenue from 2020 to 2024, indicating a growing market presence and demand for its services.

Low Debt Levels

Maintaining low debt levels provides financial flexibility and reduces risk, allowing the company to focus on growth initiatives without significant financial burden.

Improving Gross Profit Margin

Improving gross profit margins suggest better cost management and operational efficiency, which can lead to enhanced profitability over time.

Negative Factors

Persistent Losses

Ongoing losses indicate difficulties in achieving profitability, which can hinder long-term sustainability and investor confidence.

Negative Cash Flow

Negative cash flow from operations suggests challenges in generating sufficient cash internally, increasing reliance on external financing.

Declining Equity

Declining equity reflects financial vulnerability and can limit the company's ability to invest in growth opportunities or weather economic downturns.

GENinCode UK Ltd. Business Overview & Revenue Model

Company Description

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.

How the Company Makes Money

GENinCode UK Ltd. generates revenue through multiple streams, primarily by providing genetic testing services to healthcare providers and patients. The company charges fees for its testing services, which can vary depending on the complexity and scope of the tests performed. Additionally, GENI earns income through partnerships with hospitals and clinics that incorporate its genetic testing into their patient care protocols. The company may also engage in collaborations with pharmaceutical firms for research and development initiatives, further enhancing its revenue through grants or shared revenue agreements. Furthermore, GENI's software solutions may include subscription fees or licensing agreements, contributing additional revenue to its overall earnings.

GENinCode UK Ltd. Financial Statement Overview

Summary

GENinCode UK Ltd. is facing ongoing financial challenges, characterized by persistent losses and cash flow constraints. While revenue growth is a positive sign, the company's inability to achieve profitability, coupled with declining equity and reliance on external financing, highlights significant risks.

Income Statement

The income statement reveals persistent challenges, with a series of net losses despite a steady increase in revenue from 2020 to 2024. The gross profit margin has shown improvement, but the net profit margin remains negative due to significant operating losses as evidenced by negative EBIT and EBITDA margins. The company is working on expanding its revenue base; however, profitability remains a challenge.

Balance Sheet

The balance sheet shows a decline in stockholders' equity over the years, with a negative equity encountered in 2019. While the company has maintained low levels of debt, the equity ratio has decreased significantly, indicating financial vulnerability. The return on equity is negative, reflecting ongoing losses.

Cash Flow

Cash flow analysis points to significant negative operating cash flows, indicating challenges in generating cash from operations. Although there has been improvement in free cash flow over the recent period, the overall trend remains negative. The company relies heavily on financing activities to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.91M	2.70M	2.16M	1.43M	1.15M	960.80K
Gross Profit	1.37M	1.43M	1.02M	632.00K	593.00K	523.02K
EBITDA	-4.78M	-4.69M	-6.65M	-5.57M	-4.10M	-1.03M
Net Income	-4.97M	-4.43M	-7.02M	-5.56M	-4.14M	-1.17M
Balance Sheet
Total Assets	4.22M	2.66M	4.19M	11.80M	15.21M	2.42M
Cash, Cash Equivalents and Short-Term Investments	2.50M	1.17M	2.53M	9.75M	14.56M	2.00M
Total Debt	191.00K	234.00K	299.00K	354.00K	0.00	0.00
Total Liabilities	1.56M	1.54M	2.90M	3.90M	1.49M	563.50K
Stockholders Equity	2.66M	1.13M	1.29M	7.90M	13.72M	1.86M
Cash Flow
Free Cash Flow	-4.99M	-5.22M	-7.54M	-4.61M	-3.17M	-1.11M
Operating Cash Flow	-4.95M	-5.17M	-7.51M	-3.76M	-3.02M	-1.04M
Investing Cash Flow	-23.00K	50.00K	136.00K	-849.00K	-145.00K	-68.27K
Financing Cash Flow	3.63M	3.65M	-94.00K	-47.00K	15.86M	3.03M

GENinCode UK Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Negative. The current price of 2.8 is above the 20-day moving average (MA) of 2.63, below the 50-day MA of 2.87, and above the 200-day MA of 2.41, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 44.41 is Neutral, neither overbought nor oversold. The STOCH value of 7.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GENI.

GENinCode UK Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	59 Neutral	£16.95M	-7.11	-90.48%	―	37.39%	-126.19%
VRCI	58 Neutral	£11.73M	-0.32	-122.54%	―	-57.03%	-15.71%
GENI	53 Neutral	£8.03M	-1.08	-181.41%	―	12.12%	54.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	51 Neutral	£8.75M	-0.96	-153.92%	―	90.42%	79.21%
CNSL	50 Neutral	£4.64M	3.42	13.26%	―	-10.20%	714.29%
PRM	50 Neutral	£6.97M	-1.91	―	―	12.19%	18.12%

GENinCode UK Ltd. Corporate Events

GENinCode Partners with Thermo Fisher for CARDIO inCode-Score® Expansion

GENinCode UK Ltd. has announced a collaboration with Thermo Fisher Scientific to sell, distribute, and manufacture its CARDIO inCode-Score® test, which predicts genetic risk for coronary heart disease. This partnership aims to expand the test’s availability across the US and EMEA regions, leveraging Thermo Fisher’s manufacturing capabilities and distribution network. The collaboration is expected to enhance GENinCode’s market presence and accelerate the adoption of its test, which has already received New York State licensure and is included in the US Clinical Laboratory Fee Schedule. The move is part of GENinCode’s broader strategy to expand its commercial footprint and improve public health outcomes by integrating genetic risk assessments into clinical pathways.

GENinCode’s CARDIO inCode-Score® Test Gains New York State Approval

GENinCode UK Ltd. has announced the approval of its CARDIO inCode-Score® test by the New York State Department of Health, enabling full state coverage under the US Centers for Medicare and Medicaid Services. This approval allows the company to collect patient samples from New York State for testing at its California lab, marking a significant step in its US market expansion. The test, which predicts genetic risk for heart disease, is expected to enhance preventive healthcare strategies and reduce the economic burden of cardiovascular diseases. The approval also supports GENinCode’s ongoing discussions with the FDA for further market penetration.

GENinCode’s CARDIO inCode-Score® Validated for Enhanced Heart Disease Risk Prediction

GENinCode Plc has announced the publication of a significant clinical study in JACC: Advances, which validates the company’s CARDIO inCode-Score® Polygenic Risk Score for predicting coronary heart disease risk. The study, conducted by Kaiser Permanente, found that genetic risk significantly modifies the relationship between LDL-cholesterol and coronary heart disease, suggesting that integrating genetic data with clinical assessments can revolutionize cardiovascular risk stratification and prevention. This approach could lead to earlier interventions for at-risk populations, potentially improving public health outcomes and reducing the economic burden of long-term heart disease care.

GENinCode Reports Revenue Growth Amid Strategic Expansions and Challenges

GENinCode Plc reported a 15% increase in revenues for the first half of 2025, driven by growth in the UK, EU, and US markets. The company announced its first commercial contract with the NHS for ovarian cancer risk surveillance and expanded its US commercial sales of LIPID inCode® and CARDIO inCode-Score®. Despite progress, challenges such as slower NHS growth and FDA approval delays are expected to impact full-year revenue forecasts. The company remains focused on expanding its commercial programs and addressing FDA requirements to enhance its market positioning.

GENinCode and NHS Launch ROCA Surveillance Service for Ovarian Cancer

GENinCode Plc has announced a collaboration with the North Central London Cancer Alliance and University College London Hospitals NHS Foundation Trust to launch the Risk of Ovarian Cancer Algorithm (ROCA) surveillance service. This service is the first of its kind in the UK, offering women at high risk of ovarian cancer due to BRCA1 or BRCA2 gene alterations a surveillance option to defer preventative surgery. The ROCA Test, which calculates individual risk based on clinical factors, has shown a 44% reduction in late-stage ovarian cancer detections and is expected to provide cost savings to the NHS. This initiative marks a significant advancement in offering high-risk women a viable alternative to immediate surgery, enhancing early detection and treatment outcomes.

GENinCode Plc Observes Unexpected Share Price Movement Amid Ongoing FDA Discussions

GENinCode Plc has observed a sudden movement in its share price, which the company believes is not reflective of its current value. The company continues to progress in its FDA De Novo discussions and is working on collaborations for test distribution in the US and EU, with further updates expected at the interim results on 30 September 2025.